03 Aug Lisa Lix
Bio
Dr. Lisa Lix is a Professor of Biostatistics and Tier I Canada Research Chair at the University of Manitoba. She is also Director of the Data Science Platform within the George and Fay Yee Centre for Healthcare Innovation; the Data Science Platform is home to 25 staff, students, and faculty with expertise in clinical research data, biostatistics, and bioinformatics. Dr. Lix’s areas of research expertise include health services research methods, statistical methods to evaluate the quality of administrative health databases, the analysis of repeated measures and longitudinal data, and statistical methods for patient-reported outcomes. She collaborates widely on projects about population health and the association between chronic disease, prescription drug use, and quality of life. Dr. Lix has extensive experience working with administrative health databases from multiple Canadian provinces and this has provided her with unique insights into new methodological research opportunities. She is a research scientist with the Manitoba Centre for Health Policy. Dr. Lix has been actively participating in Canadian Network for Observational Drug Effect Studies (CNODES) since July 2011. Since her involvement, she served as the methods liaison on several studies and is a member of the Training and Methods Teams. In October 2019, Dr. Lix was appointed lead of the CNODES Database Team and member of the CNODES Steering Committee.
CNODES Projects
Serotonin-norepinephrine reuptake inhibitors and the risk of AKI: A cohort study of eight administrative databases and meta-analysis
, ManitobaComparative safety of direct oral anticoagulants and warfarin in patients with venous thromboembolism: a multicenter observational study of administrative databases
Methods Lead, ManitobaData variability across Canadian administrative health databases: Differences in content, coding, and completeness
Collaborator, ManitobaSodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Methods LeadSodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study
Methods LeadSodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study
Methods LeadSodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study
Methods LeadValidity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
Project Lead, ManitobaCharacteristics of new users of newer antidiabetic drugs in Canada and the United Kingdom
Methods LeadMethadone containing products used for opioid use disorder
Methods Lead- Methods Lead
Validity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study
Project Co-LeadUtilization Analysis of Tofacitinib and Other Drugs Among Individuals with Ulcerative Colitis: Feasibility Analysis
Methods LeadUse of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update
Methods LeadUse of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update
Site Investigator, ManitobaIntentional Self-Harm with GLP-1 Receptor Agonists for Diabetes
Methods Lead